BMRA: Biomerica, Inc. Stock

by  •  • Comments Off on BMRA: Biomerica, Inc. Stock

SIC 2835 – In Vitro and In Vivo Diagnostic Substances

Valuation
Market Cap ($M) 11.44
Enterprise Value ($M) 6.12
Book Value ($M) 7.81
Book Value / Share 0.46
Price / Book 1.46
NCAV ($M) 6.31
NCAV / Share 0.38
Price / NCAV 1.81

Profitability (mra)
Return on Invested Capital (ROIC) -0.73
Return on Assets (ROA) -0.77
Return on Equity (ROE) -1.06

Liquidity (mrq)
Quick Ratio 3.37
Current Ratio 4.44

Balance Sheet (mrq) ($M)
Current Assets 8.85
Assets 10.34
Liabilities 2.53
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Granahan Investment Management Inc/ma 6.44 -3.57
02-09 13G Wasatch Advisors Inc

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2024 or ☐ TRANSITION REPORT PURSUA
2024-01-16 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUA
2023-10-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2023 or ☐ TRANSITION REPORT PURSUANT
2023-08-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2023 or ☐ Transition Report Pursuant to Section

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 15,958 95,316 16.74
2024-04-25 27,230 19,852 137.17
2024-04-24 155,135 75,557 205.32
2024-04-23 3,130 5,420 57.75
2024-04-22 19,381 2,237 866.38

(click for more detail)

Similar Companies
BFRI – Biofrontera Inc. BGXX – Bright Green Corporation
BIVI – BioVie Inc. BNTC – Benitec Biopharma Inc.
BON – Bon Natural Life Limited


Financial data and stock pages provided by
Fintel.io